Bob Ingram is in no danger of getting bored.
On May 18, the retired CEO of Glaxo Wellcome plans to join the board of PPD, the Wilmington-based pharmaceutical research company with a large operation in the Triangle. It's just the latest role for one of this region's busiest and most experienced corporate leaders.
Ingram, 68, is also a general partner with Durham-based investment firm Hatteras Venture Partners. In January, he became chairman of Elan Corp., an Irish biotechnology firm.
He's also on the boards of other public companies Allergan, Cree, Edwards Lifesciences and Valeant Pharmaceuticals. And he serves as a strategic advisor to GlaxoSmithKline CEO Andrew Witty.